Fulgent Genetics, Inc. FLGT Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s cash provided by (used in) investing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s cash provided by (used in) investing activity, including discontinued operation?
- Fulgent Genetics, Inc. (FLGT) reported cash provided by (used in) investing activity, including discontinued operation of $10.94M in Q1 2026.
- How has Fulgent Genetics, Inc.'s cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
- Fulgent Genetics, Inc.'s cash provided by (used in) investing activity, including discontinued operation decreased by 60.6% year-over-year, from $27.73M to $10.94M.
- What is the long-term trend for Fulgent Genetics, Inc.'s cash provided by (used in) investing activity, including discontinued operation?
- Over 2 years (2021 to 2025), Fulgent Genetics, Inc.'s cash provided by (used in) investing activity, including discontinued operation has grown at a -54.9% compound annual growth rate (CAGR), from -$546.55M to $111.37M.
- What does cash provided by (used in) investing activity, including discontinued operation mean?
- The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.